Front. Bioeng. Biotechnol. Frontiers in Bioengineering and Biotechnology Front. Bioeng. Biotechnol. 2296-4185 Frontiers Media S.A. 1631667 10.3389/fbioe.2025.1631667 Bioengineering and Biotechnology Correction Correction: Baicalin-modifed polyethylenimine for miR-34a efficient and safe delivery Wang et al. 10.3389/fbioe.2025.1631667 Wang Yingying 1 2 † Wang Baiyan 1 † Xiao Yangfan 2 Cai Qingchun 3 Xing Junyue 2 Tang Hao 2 * Li Ruiqin 4 * Zhang Hongtao 5 6 7 8 * 1 Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China 2 National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People’s Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China 3 Department of Clinical Lab, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China 4 Academy of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, China 5 Blood Purification Center, The People’s Hospital of Zhengzhou University, Zhengzhou, China 6 Blood Purification Center, Henan Provincial People’s Hospital, Zhengzhou, China 7 Institute of Nephrology, Mathura, Henan, China 8 Department of Nephrology Henan Provincial People’s Hospital, Zhengzhou, China

Edited and reviewed by: Gianni Ciofani, Italian Institute of Technology (IIT), Italy

 *Correspondence: Hao Tang, tangpku_zzuhao@zzu.edu.cn; Ruiqin Li, lirqin@yeah.net; Hongtao Zhang, zhtzzu@zzu.edu.cn

These authors have contributed equally to this work

 15 07 2025 2025 13 1631667 20 05 2025 30 06 2025 Copyright © 2025 Wang, Wang, Xiao, Cai, Xing, Tang, Li and Zhang. 2025 Wang, Wang, Xiao, Cai, Xing, Tang, Li and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery by Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2023). Front. Bioeng. Biotechnol. 11:1290413. doi: 10.3389/fbioe.2023.1290413 baicalin lung cancer gene therapy miR-34a hydrophobic modification section-at-acceptance Nanobiotechnology

In the published article, there was an error in Western blot of Figure 4C as published. An extra GAPDH band image was included in the original Figure 4C. The corrected Western blot of Figure 4C and its caption FIGURE 4 BA-PEI/miR-34a induced apoptosis of tumor cell A549. (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. appear below.

BA-PEI/miR-34a induced apoptosis of tumor cell A549. (A) Cell apoptosis analysis using flow cytometry, based on the control, miR-34a, PEI, BAPEI, PEI/miR-34a, and BA-PEI/miR-34a. (B) Quantitative analysis of (A). (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. (D) Quantitative analysis of (C). *p <0.05; **p <0.01; ns, not significant.

Four-part figure showing experimental data:A) Six scatter plots illustrating cell populations with different treatments: Control, Bacalin, Bacalin/miR-34a, miR-34a, PEI, and PEI/miR-34a.B) Bar graph depicting apoptosis rates (%) for various treatments, showing a significant increase (* marked) in the BA-PEI/miR-34a group.C) Western blot images for PTEN, GAPDH, and pro-caspases 3, 8, 9 across different treatment groups.D) Bar chart displaying gray value ratios for PTEN and pro-caspases, indicating significant changes in expression levels with specific treatments.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.